Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity

International Journal of Cancer

Volumn 134, Issue 4, 2014, Pages 873-884

  Verschuere, Tina ^a   Toelen, Jaan ^a   Maes, Wim ^a   Poirier, Françoise ^b   Boon, Louis ^c   Tousseyn, Thomas ^d   Mathivet, Thomas ^e   Gerhardt, Holger ^e,f   Mathieu, Veronique ^g   Kiss, Robert ^g   Lefranc, Florence ^h   Van Gool, Stefaan W ^a   De Vleeschouwer, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b INSTITUT JACQUES MONOD   (France)

^c BIOCEROS   (Netherlands)

^d DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^g FREE UNIVERSITY OF BRUSSELS   (Belgium)

^h ERASME HOSPITAL   (Belgium)

Author keywords

angiogenesis; dendritic cell immunotherapy; galectin 1; glioblastoma; tumor infiltrating myeloid cells

Indexed keywords

DENDRITIC CELL VACCINE; GALECTIN 1; GAMMA INTERFERON; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GLIOMA; GLIOMA CELL; IMMUNOREGULATION; INNATE IMMUNITY; INTERFERON PRODUCTION; MACROPHAGE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84890126632     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28426     Document Type: Article

References (42)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
3. Ardon H, Van Gool SW, Verschuere T, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 2012; 61: 2033-44.
4. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14: 3098-104.
5. Ehtesham M, Black KL, Yu JS,. Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 2004; 11: 192-207.
6. Waziri A,. Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am 2010; 21: 31-42.
7. Rabinovich GA, Toscano MA,. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009; 9: 338-52.
8. Perillo NL, Pace KE, Seilhamer JJ, et al. Apoptosis of T cells mediated by galectin-1. Nature 1995; 378: 736-9.
9. Toscano MA, Bianco GA, Ilarregui JM, et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007; 8: 825-34.
10. Chung CD, Patel VP, Moran M, et al. Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 2000; 165: 3722-9.
11. Cedeno-Laurent F, Watanabe R, Teague JE, et al. Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 2012; 119: 3534-8.
12. He J, Baum LG,. Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab Invest 2006; 86: 578-90.
13. Garin MI, Chu CC, Golshayan D, et al. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007; 109: 2058-65.
14. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5: 241-51.
15. Cedeno-Laurent F, Opperman MJ, Barthel SR, et al. Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J Invest Dermatol 2012; 132: 410-20.
16. Gandhi MK, Moll G, Smith C, et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007; 110: 1326-9.
17. Le Mercier M, Fortin S, Mathieu V, et al. Galectins and gliomas. Brain Pathol 2010; 20: 17-27.
18. Rorive S, Belot N, Decaestecker C, et al. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 2001; 33: 241-55.
19. Verschuere T, De Vleeschouwer S, Lefranc F, et al. Galectin-1 and immunotherapy for brain cancer. Expert Rev Neurother 2011; 11: 533-43.
20. Szatmari T, Lumniczky K, Desaknai S, et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006; 97: 546-53.
21. Poirier F, Robertson EJ,. Normal development of mice carrying a null mutation in the gene encoding the L14 S-type lectin. Development 1993; 119: 1229-36.
22. Maes W, Rosas GG, Verbinnen B, et al. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol 2009; 11: 529-42.
23. Mathieu V, Le Mercier M, De Neve N, et al. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol 2007; 127: 2399-410.
24. Gabrilovich DI, Nagaraj S,. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
25. Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 2006; 103: 15975-80.
26. Le Mercier M., Mathieu V, Haibe-Kains B, et al. Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol 2008; 67: 456-69.
27. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-55.
28. Nishie A, Ono M, Shono T, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 1999; 5: 1107-13.
29. Galarneau H, Villeneuve J, Gowing G, et al. Increased glioma growth in mice depleted of macrophages. Cancer Res 2007; 67: 8874-81.
30. Zhu X, Fujita M, Snyder LA, et al. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol 2011; 104: 83-92.
31. Leung SY, Wong MP, Chung LP, et al. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 1997; 93: 518-27.
32. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-43.
33. Allavena P, Mantovani A,. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012; 167: 195-205.
34. Correa SG, Sotomayor CE, Aoki MP, et al. Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. Glycobiology 2003; 13: 119-28.
35. Ilarregui JM, Rabinovich GA,. Tolerogenic dendritic cells in the control of autoimmune neuroinflammation: an emerging role of protein-glycan interactions. Neuroimmunomodulation 2010; 17: 157-60.
36. Starossom SC, Mascanfroni ID, Imitola J, et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 2012; 37: 249-63.
37. Barrionuevo P, Beigier-Bompadre M, Ilarregui JM, et al. A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J Immunol 2007; 178: 436-45.
38. Santucci L, Fiorucci S, Cammilleri F, et al. Galectin-1 exerts immunomodulatory and protective effects on concanavalin A-induced hepatitis in mice. Hepatology 2000; 31: 399-406.
39. He J, Baum LG,. Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 2004; 279: 4705-12.
40. Stannard KA, Collins PM, Ito K, et al. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model. Cancer Lett 2010; 299: 95-110.
41. Belanis L, Plowman SJ, Rotblat B, et al. Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters. Mol Biol Cell 2008; 19: 1404-14.
42. Le Mercier M, Lefranc F, Mijatovic T, et al. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 2008; 229: 172-83.